Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection?
Antibody to the non-serotype-specific cell wall polysaccharide (CWPS) of Streptococcus pneumoniae has been said to confer a degree of non-serotype-specific protection against pneumococcal infection. The hypothesis underlying the present study was that if this antibody is protective, relatively higher levels are likely to be detected in patients who are colonized by pneumococci but do not have infection, those who have febrile bronchitis but do not have pneumonia, and those who have pneumococcal pneumonia but are not bacteremic. Mean IgG reactive with CWPS by ELISA in 15 healthy young adults was 43.9 micrograms/ml and in 126 randomly selected hospital patients of all ages was 41.9 micrograms/ml. In subjects with chronic bronchitis with or without known pneumococcal carriage, mean anti-CWPS IgG was 87.7 micrograms/ml. In three groups of patients (3 with acute purulent tracheobronchitis, 13 with nonbacteremic pneumococcal pneumonia, and 14 with S. pneumoniae bacteremia) at the time of adm
- How can I determine whether research proposed in my application involves human subjects if I will only use human specimens (and/or cell lines, and/or data) for part of the project?
- HOW DOES THE IRB PROTECT THE RIGHTS AND WELFARE OF HUMAN RESEARCH SUBJECTS?
- What does the cell wall do to protect the cell?